# Thinner cortex is associated with psychosis onset in individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group mega-

## 4 analysis

Short Title: Cortical Thickness in CHR

### 8 Authors

6

7

9 10 Jalbrzikowski, Maria: Haves, Rebecca A.: Wood, Stephen J.: Nordholm, Dorte: Zhou, Juan H.: Fusar-Poli, Paolo; Uhlhaas, Peter J.; Takahashi, Tsutomu; Sugranyes, Gisela; Kwak, YooBin; 11 Mathalon, Daniel H.; Katagiri, Naoyuki; Hooker, Christine I.; Smigielski, Lukasz; Colibazzi, 12 Tiziano; Via, Esther; Tang, Jinsong; Koike, Shinsuke; Rasser, Paul E.; Michel, Chantal; 13 Lebedeva, Irina; ten Velden Hegelstad, Wenche; de la Fuente-Sandoval, Camilo; Waltz, James 14 A.; Mizrahi, Romina R.M.; Corcoran, Cheryl; Resch, Franz; Tamnes, Christian K.; Haas, 15 Shalaila S.: Lemmers-Jansen, Imke L.J.: Agartz, Ingrid: Allen, Paul: Andreassen, Ole A.: 16 Atkinson, Kimberley; Bachman, Peter; Baeza, Inmaculada; Baldwin, Helen; Bartholomeusz, Cali 17 F.;Brønnick, Kolbjørn S.;Catalano, Sabrina; Chee, Michael W.L.;Chen, Xiaogang; Cho, Kang 18 Ik K.; Cooper, Rebecca E.; Cropley, Vanessa L.; Dolz, Montserrat; Ebdrup, Bjørn H.; Fortea, 19 Adriana; Glenthøj, Louise B.; Glenthøj, Birte Y.; de Haan, Lieuwe; Hamilton, Holly K.; Harris, 20 Mathew A.: Haut, Kristen M.: He, Ying: Heekeren, Karsten: Heinz, Andreas: Hubl, Daniela: 21 Hwang, WuJeong; Kaess, Michael; Kasai, Kiyoto; Kim, Minah; Kindler, Jochen; Klaunig, 22 Mallory, J.; Kristensen, TinaD.; Kwon, Jun Soo; Lawrie, Stephen M.; Lee, Jimmy; León-Ortiz, 23 Pablo; Lin, Ashleigh; Loewy, Rachel L.; Ma, Xiaoqian; Mathalon, Daniel H.; McGorry, Patrick; 24 McGuire, Philip; Mizuno, Masafumi; Møller, PaulMoncada-Habib, Toma ; Munoz-Samons, 25 Daniel: Nelson, Barnaby: Nemoto, Takahiro: Nordentoft, Merete: Omelchenko, Maria A.: 26 Oppedal, Ketil; Ouyang, Lijun; Pantelis, Christos; Pariente, Jose C.; Raghava, Jayachandra; 27 Reyes-Madrigal, Francisco; Roach, Brian J.; Røssberg, Jan I.; Rössler, Wulf; Salisbury, Dean F.; 28 Sasabayashi, Daiki; Schall, Ulrich; Schiffman, Jason; Schlagenhauf, Florian; Schmidt, Andre; 29 Sørensen, Mikkel E.; Suzuk Michio; Theodoridou, Anastasia; Tomyshev, Alexander S.; Tor, 30 Jordina; Vaernes, Tor G; Velakoulis, Dennis; Venegoni, Gloria D.; Vinogradov, Sophia; 31 Wenneberg, Christina; Westlye, Lars T.; Yamasue, Hidenori; Yuan, Liu; Yung, Alison R.; van 32 Amelsvoort, Thérèse A.M.J.; Turner, Jessica A.; van Erp, TheoG.M.; Thompson, Paul M.; Hernaus, 33 Dennis. 34

34 35

### **Author Affiliations**

37

Amsterdam UMC, Amsterdam, TheNetherlands (de Haan); Arkin, Amsterdam, TheNetherlands

39 (de Haan); Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research,

CINS, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark (Ebdrup,

Glenthøj, Sørensen, Kristensen); Center for Evolutionary Cognitive Sciences, Graduate School

42 of Art and Sciences, The University of Tokyo (Koike); Center for Sleep and Cognition, Yong Loo

Lin School of Medicine, National University of Singapore, Singapore (Zhou); Center for the

Neurobiology of Learning and Memory, 309 Qureshey Research Lab, Irvine, CA, USA (Van

- Erp); Center for Translational Magnetic Resonance Research, Yong Loo Lin School of
- 46 Medicine, National University of Singapore, Singapore (Zhou); Centre for Clinical Intervention
- and Neuropsychiatric Schizophrenia Research (CINS), Glostrup, Denmark (Raghava); Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne

University, Melbourne, Australia (Pantelis, Cropley); Centre for Neuropsychiatric Schizophrenia 48 49 Research, CNSR, Glostrup, Denmark (Raghava); Centre for Sleep and Cognition, Yong Loo Lin 50 School of Medicine, National University of Singapore, Singapore (Chee); Centre for Youth 51 Mental Health, University of Melbourne, Australia (Wood, Bartholomeusz, Nelson); Child and Adolescent Mental Health Research Group, Institut de Recerca Sant Joan de Déu, Barcelona, 52 Spain (Via, Dolz, Muñoz-Samons, Tor); Child and Adolescent Psychiatry and Psychology 53 54 Department, Hospital Sant Joan de Déu, Barcelona, Spain (Via, Dolz Abadia, Muñoz-Samons, 55 Tor); Clinic for Child and Adolescent Psychiatry, University Hospital of Heidelberg, Heidelberg, 56 Germany (Resch): Clinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA, USA (Van Erp); Columbia 57 University Department of Psychiatry, New York, USA (Colibazzi); Copenhagen Research 58 59 Center for Mental Health - CORE, Mental Health Center Copenhagen, Copenhagen University 60 Hospital, Denmark (Nordholm, Glenthøj, Kristensen, Nordentoft, Wenneberg); Department for 61 Mental Health Research and Development, Division of Mental Health and Addiction, Vestre 62 Viken Hospital Trust, Norway (Møller); Department of Brain and Behavioral Sciences, University 63 of Pavia, Italy (Fusar-Poli); Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Republic of Korea (Kwak, Hwang); Department of Child 64 65 and Adolescent Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic Barcelona, Fundació Clínic Recerca Biomèdica, Universitat de Barcelona, Spain (Fortea): 66 67 Department of Child and Adolescent Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunver (IDIBAPS), 68 CIBERSAM, Universitat de Barcelona, Spain (Sugranyes, Baeza); Department of Child and 69 70 Adolescent Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Switzerland 71 (Smigielski); Department of Child and Adolescent Psychiatry, Center of Psychosocial Medicine, University of Heidelberg, Heidelberg, Germany (Kaess); Department of Child and Adolescent 72 Psychiatry, Charité Universitätsmedizin, Berlin, Germany (Uhlhaas); Department of Clinical 73 74 Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark 75 (Ebdrup, Glenthøj); Department of Clinical Physiology, Nuclear Medicine and PET, Functional Imaging Unit, Glostrup, Denmark (Raghava); Department of Neuropsychiatry, Graduate School 76 of Medicine, The University of Tokyo, Japan (Kasai); Department of Neuropsychiatry, Seoul 77 78 National University Hospital, Republic of Korea (Kim, Kwon); Department of Neuropsychiatry, Toho University School of Medicine, Japan (Katagiri, Mizuno, Nemoto); Department of 79 Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical 80 81 Sciences, Toyama, Japan (Takahashi, Sasabayashi, Suzuki); Department of Pharmacology and 82 Toxicology, University of Toronto, Canada (Koppel); Department of Psychiatric Research, 83 Diakonhjemmet Hospital, Oslo, Norway (Agartz); Department of Psychiatry & Behavioral Sciences, University of California, San Francisco, CA, USA (Hamilton); Department of 84 Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Maastricht 85 86 University, The Netherlands (van Amelsvoort, Hernaus); Department of Psychiatry (UPK), University of Basel, Switzerland (Borgwardt, Schmidt); Department of Psychiatry and 87 Behavioral Sciences, Rush University Medical Center, Chicago IL (Hooker); Department of 88 Psychiatry and Psychotherapy I, LVR-Hospital Cologne, Cologne, Germany 89 90 (Heekeren): Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin 91 Institute of Health, Germany (Heinz, Schlagenhauf); Department of Psychiatry and 92 93 Psychotherapy, Charité Universitätsmedizin, Berlin, Germany (Rössler); Department of 94 Psychiatry and Psychotherapy, University of Lübeck, Germany (Borgwardt); Department of Psychiatry, Hamamatsu University School of Medicine, Hamamatsu City, Japan (Yamasue); 95 Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA 96 97 (Corcoran, Haas); Department of Psychiatry, Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA (Cho); Department of Psychiatry, 98

99 Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, 100 Switzerland (Smigielski, Heekeren, Rössler, Theodoridou); Department of Psychiatry, Rush 101 University Medical Center, Chicago, IL, USA (Haut); Department of Psychiatry, Seoul National 102 University College of Medicine, Republic of Korea (Kim, Kwon); Department of Psychiatry, Sir 103 Run Run Shaw Hospital, School of Medicine, Zheijang University, Hangzhou, Zheijang, China 104 (Tang); Department of Psychiatry, the Second Xiangya Hospital, Central South University, 105 Changsha, Hunan, China (Chen, He, Ma, Ouyang, Yuan); Department of Psychiatry, University 106 of California, San Francisco, CA, USA (Mathalon, Loewy, Roach); Department of Psychiatry, 107 University of Edinburgh, UK (Atkinson, Harris); Department of Psychiatry, University of 108 Minnesota, MN, USA (Vinogradov); Department of Psychiatry, University of Pittsburgh, PA, USA 109 (Jalbrzikowski, Hayes, Bachman, Catalano, Salisbury); Department of Psychological Science, 110 University of California, Irvine, CA, USA (Schiffman); Department of Psychology, University of 111 Maryland, Baltimore County, MD, USA (Klaunig, Schiffman); Department of Psychology, 112 University of Oslo, Norway (Westlye): Department of Psychology, University of Roehampton, 113 London, UK (Allen): Department of Psychosis Studies, Institute of Psychiatry, Psychology and 114 Neuroscience, King's College London, UK (Lemmers-Jansen, Baldwin); Department of 115 Psychosis, Institute of Mental Health, Singapore (Lee); Division of Psychiatry, University of 116 Edinburgh, Edinburgh, UK (Lawrie, Venegoni); Douglas Research Center, Montreal, Canada 117 (Mizrahi); Early Intervention in Psychosis Advisory Unit for South-East Norway, TIPS SørØst, 118 Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (Værnes); EPIC 119 Lab, Department of Psychosis Studies, King's College London, UK (Fusar-Poli); Faculty of 120 Behavioural and Movement sciences, Department of Clinical, Neuro and Developmental 121 Psychology, Vrije Universiteit Amsterdam, The Netherlands (Lemmers-Jansen); Faculty of 122 Social Sciences, University of Stavanger, Norway (Hegelstad); Florey Institute of Neuroscience 123 and Mental Health, Australia (Pantelis); Georgia State University, Atlanta, GA, USA (Turner); 124 Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan, China (Ouyang, 125 Yuan, Yung); Imaging Genetics Center, Mark & Mary Stevens Institute for Neuroimaging & 126 Informatics, Keck USC School of Medicine, Los Angeles, CA, USA (Thompson); Institute of 127 Neuroscience and Psychology, University of Glasgow, Glasgow, UK (Uhlhaas): James J Peters VA, Bronx, NY, USA (MIRECC) (Corcoran); Key Laboratory of Medical Neurobiology of 128 129 Zhejiang Province, Zhejiang, China (Tang); King's College London, UK (McGuire); Laboratory of 130 Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico 131 (de la Fuente-Sandoval, León-Ortiz, Moncada-Habib, Reves-Madrigal); Lee Kong Chian School 132 of Medicine, Nanyang Technological University, Singapore (Lee); Maastricht University, The 133 Netherlands (Venegoni): Magnetic Resonance Imaging core facility. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (Pariente); Maryland Psychiatric 134 135 Research Center, University of Maryland School of Medicine, MD, USA (Waltz); McGill 136 University, Montreal, Canada (Mizrahi); Melbourne Neuropsychiatry Centre, Department of 137 Psychiatry, University of Melbourne & Melbourne Health, Melbourne, Australia (Cooper, 138 Cropley, Velakoulis); Mental Health Research Center, Moscow, Russia (Lebedeva, 139 Omelchenko, Tomyshey): National Clinical Research Center for Geriatric Disorders. Xiangya Hospital, Central South University, Changsha, China (Chen, Ouyang, Yuan, Yung); 140 141 Neuropsychiatry, The Royal Melbourne Hospital, Australia (Velakoulis); New York State 142 Psychiatric Institute, NY, USA (Colibazzi); NIHR Maudsley Biomedical Research Centre (South 143 London and Maudsley NHS Foundation Trust & King's College London), UK (Baldwin); 144 NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of 145 Clinical Medicine, University of Oslo, Oslo, Norway (Tamnes, Agartz, Andreassen, Røssberg, 146 Værnes, Westlye): Orygen, The University of Melbourne, Melbourne, Australia (Wood, 147 Bartholomeusz, McGorry, Nelson, Yung); Priority Centre for Brain & Mental Health Research, 148 The University of Newcastle, Australia 149 (Rasser, Schall); Priority Research Centre for Stroke and Brain Injury, The University of

149 (Rasser, Schall); Priority Research Centre for Stroke and Brain Injury, The University of Newcastle, Australia (Rasser); Priority Research Centre Grow Up Well, The University of

- 150 Newcastle, Australia (Schall); PROMENTA Research Center, Department of Psychology,
- 151 University of Oslo, Norway (Tamnes); Psychosis Studies, Institute of Psychiatry, Psychology
- and Neuroscience, King's College London, UK (Allen); Research Center for Idling Brain
- 153 Science, University of Toyama, Toyama, Japan (Takahashi, Sasabayashi, Suzuki); San
- 154 Francisco Veterans Affairs Health Care System, San Francisco, CA (Hamilton); School of
- 155 Psychology, University of Birmingham, UK (Wood); Stavanger Medical Imaging Laboratory
- 156 (SMIL), Stavanger University Hospital, Norway (Oppedal); Telethon Kids Institute, The
- 157 University of Western Australia, Perth, Australia (Lin); The University of Tokyo Institute for
- 158 Diversity and Adaptation of Human Mind (UTIDAHM), Japan (Koike, Kasai); TIPS Network for
- 159 Clinical Research in Psychosis, Stavanger University Hospital, Norway (Hegelstad);
- 160 Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University
- 161 of Bern, Bern, Switzerland (Hubl); University Hospital of Child and Adolescent Psychiatry and
- 162 Psychotherapy, University of Bern, Bern, Switzerland (Michel, Kaess, Kindler)
- 163 164

- 165 Key words: magnetic resonance imaging, cortical thickness, ultra high-risk for psychosis,
- 166 prodromal, schizophrenia, at-risk mental states, gray matter, brain volume, CHR, clinical high 167 risk
- 168

#### 169 Address for Correspondence

- 170 3501 Forbes Ave, Suite 430
- 171 Pittsburgh, PA, United States of America, 15213
- 172 jalbrzikowskime@upmc.edu/dennis.hernaus@maastrichtuniversity.nl
- 173 Word Count (Total): 3413 (including Key Points, Abstract, and Main Text)
- 174 Word Count (Abstract): 332 (max 350)
- 175 Word Count (Body): 2961 (max 3000)
- 176 Tables: 1 main text/20 supplemental
- 177 Figures: 3 main text/5 supplemental
- 178 Citation no.: 123
- 179

### 180 Key Points

181

182 Question: How do baseline brain morphometric features relate to later psychosis conversion in183 individuals at clinical high risk (CHR)?

- 184 **Findings:** In the largest coordinated international analysis to date, reduced baseline cortical
- 185 thickness, but not cortical surface area or subcortical volume, was more pronounced in CHR, in
- a manner highly consistent with thinner cortex in established psychosis. Regions that displayed
- 187 greater cortical thinning in future psychosis converters additionally displayed abnormal
- 188 associations with age.
- 189 **Meaning:** CHR status and later transition to psychosis is robustly associated with reduced cortical
- 190 thickness. Abnormal age associations and specificity to cortical thickness may point to aberrant
- 191 postnatal brain development in CHR, including pruning and myelination.

#### 192 Abstract

193

194 Importance: The ENIGMA clinical high risk for psychosis (CHR) initiative, the largest pooled 195 CHR-neuroimaging sample to date, aims to discover robust neurobiological markers of 196 psychosis risk in a sample with known heterogeneous outcomes.

197

198 **Objective:** We investigated baseline structural neuroimaging differences between CHR 199 subjects and healthy controls (HC), and between CHR participants who later developed a 200 psychotic disorder (CHR-PS+) and those who did not (CHR-PS-). We assessed associations 201 with age by group and conversion status, and similarities between the patterns of effect size 202 maps for psychosis conversion and those found in other large-scale psychosis studies.

203

204 Design, Setting, and Participants. Baseline T1-weighted MRI data were pooled from 31 205 international sites participating in the ENIGMA CHR Working Group. MRI scans were processed 206 using harmonized protocols and analyzed within a mega- and meta-analysis framework from 207 January-October 2020.

208

209 Main Outcome(s) and Measure(s): Measures of regional cortical thickness (CT), surface area

- 210 (SA), and subcortical volumes were extracted from T1-weighted MRI scans. Independent 211 variables were group (CHR, HC) and conversion status (CHR-PS+, CHR-PS-, HC).
- 212

213 **Results:** The final dataset consisted of 3,169 participants (CHR=1,792, HC=1,377, age range: 214 9.5 to 39.8 years, 45% female). Using longitudinal clinical information, we identified CHR-PS+ 215 (N=253) and CHR-PS- (N=1,234). CHR exhibited widespread thinner cortex compared to HC 216 (average d=-0.125, range: -0.09 to -0.17), but not SA or subcortical volume. Thinner cortex in 217 the fusiform, superior temporal, and paracentral regions was associated with psychosis 218 conversion (average d=-0.22). Age showed a stronger negative association with left fusiform 219 and left paracentral CT in HC, compared to CHR-PS+. Regional CT psychosis conversion effect 220 sizes resembled patterns of CT alterations observed in other ENIGMA studies of psychosis. 221

222 Conclusions and Relevance: We provide evidence for widespread subtle CT reductions in 223 CHR. The pattern of regions displaying greater CT alterations in CHR-PS+ were similar to those 224 reported in other large-scale investigations of psychosis. Additionally, a subset of these regions 225 displayed abnormal age associations. Widespread CT disruptions coupled with abnormal age 226 associations in CHR may point to disruptions in postnatal brain developmental processes.

227

### 228 1. INTRODUCTION

229 The clinical high-risk paradigm is a widely used framework to investigate mechanisms 230 underlying psychosis vulnerability. Help-seeking individuals who do not meet diagnostic criteria 231 for a psychotic disorder, but typically present with subthreshold psychotic symptoms and accumulating risk factors, are considered at clinical high-risk (CHR) for developing psychosis<sup>1–3</sup>. 232 233 An estimated 18-20% of CHR individuals develop a psychotic disorder within 2 years of identification<sup>4</sup>, although conversion rates vary<sup>5–11</sup>, likely due to heterogeneous recruitment and 234 sampling strategies, and interventions applied<sup>2,13</sup>. However, despite decades of research, the 235 236 nature of morphometrical alterations associated with psychosis conversion remains largely 237 unknown. Here, we aim to address this question by combining all available structural 238 neuroimaging data in CHR to date, in an attempt to better understand brain mechanisms 239 associated with psychosis risk and conversion in this population.

240 A large body of work has used structural magnetic resonance imaging (sMRI) to investigate morphometric brain alterations in CHR individuals<sup>14–37</sup>. However, the extent to which 241 characteristic baseline structural neuroimaging differences exist between those at CHR who 242 243 later develop a psychotic disorder (CHR-PS+) compared to those who do not (CHR-PS-) is 244 debated. Many studies failed to find baseline differences between CHR-PS+ and CHR-PS-245 <sup>15,35,38,39</sup>, though a meta-analysis and multi-center study found lower prefrontal and temporal volumes or cortical thickness (CT) in CHR-PS+<sup>40,41</sup>. High attrition rates in CHR samples<sup>42-44</sup>, 246 coupled with low psychosis conversion rates<sup>4,45</sup>, often yield insufficient power to detect between-247 group structural brain differences. Moreover, small sample sizes can be associated with inflated 248 effect sizes<sup>46,47</sup>, so effect sizes of prior studies that found structural brain alterations in CHR may 249 be overestimated. Although multi-site consortia aim to address these challenges<sup>34,48–50</sup>, the 250 largest published sMRI studies to date included fewer than 50 CHR-PS+<sup>38,41</sup>. Furthermore, it is 251 252 currently unknown whether group differences are robust enough to predict outcomes.

253 Importantly, many CHR participants are adolescents or young adults, a timeframe associated with psychosis onset<sup>51,52</sup>. Several brain regions implicated in psychosis show 254 protracted developmental courses continuing through adolescence<sup>53–63</sup>, suggesting that 255 morphometric alterations associated with psychosis risk vary with age. Indeed, there are 256 developmental influences on psychotic symptom presentation<sup>64–68</sup>, perhaps driven by 257 258 differences in regional brain changes. It is not fully understood how age-related patterns in brain 259 morphometry in CHR differ from normal development. Thus, using a developmental framework 260 to examine whether morphometric alterations in CHR are influenced by age may provide 261 important insights into mechanisms associated with psychosis risk, and the stability of 262 neuroimaging measures associated with psychosis risk across development.

Finally, it is unknown whether baseline brain alterations associated with future
 conversion to psychosis resemble those observed in other large-scale psychosis studies.
 Understanding whether morphometric alterations in CHR overlap with those observed in
 individuals who have schizophrenia<sup>69-71</sup> and individuals with a genetic subtype of psychosis<sup>72,73</sup>
 will provide insights into convergent or distinct alterations across the psychosis spectrum.

To address these questions, we founded the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Clinical High Risk Working Group in 2018. Using baseline

sMRI data and longitudinal clinical information from 31 sites, this study addressed the followingquestions:

272 273

274

275

279

280

281

- 1. Do CHR and healthy control (HC) participants differ in CT, surface area (SA), and/or subcortical volumes?
- 2. Is there a neuroanatomic signature associated with future transition to a psychotic disorder (CHR-PS+ versus CHR-PS- versus HC)?
- 2763. Do structural neuroimaging measures identified in Aims 1 and 2 display group277differences in age associations, suggestive of abnormal developmental278trajectories?
  - 4. Is the pattern of morphometric alteration associated with psychosis conversion similar to that observed in ENIGMA studies of psychosis?
- 282 283 **2. METHODS**
- 284

### 285 Participants

286 We included 1,792 CHR and 1,377 HC from 31 sites participating in the ENIGMA CHR Working Group (Table 1). CHR data consisted of CHR-PS+ (N=253), CHR-PS- (N=1,234), and CHR 287 288 individuals without follow-up data (CHR-UNK, N=305). CHR participants met CAARMS (N=821) 289 or SIPS (N=971) CHR criteria (see details in Supplement). Site-specific inclusion/exclusion 290 criteria are detailed in **eTable 1**. All sites obtained Institutional Review Board approval prior to 291 data collection. Informed written consent was obtained from every participant or the participant's 292 guardian (for participants <18 years). All studies were conducted in accordance with the 293 Declaration of Helsinki<sup>74</sup>.

294

### 295 Image Acquisition and Processing

296 Thirty-one sites contributed T1-weighted MRI brain scans from 50 MRI scanners (eTable
297 2 for MRI acquisition details). We conducted power calculations to estimate the sample size
298 necessary to detect statistically significant effects (see Supplement for details).

We extract structural gray matter measures of 68 CT, 68 SA measures, and 16 subcortical volume measures using the FreeSurfer analysis software<sup>75–78</sup>. We implemented the ENIGMA consortium quality assessment pipeline<sup>70,73,79–82</sup> (**Supplement** for further details).

- 302 Prior to conducting the mega-analysis, all neuroimaging data were adjusted for scanner 303 protocol effects using neuroComBat<sup>83</sup>, a modified version of ComBat<sup>84</sup> that increases the 304 statistical power and precision of neuroimaging effect size estimates<sup>83</sup>.
- 305
- 306

### 307 Statistical Analyses

308

309 Group and conversion-related differences in structural neuroimaging metrics

- 310 We assessed group differences using general linear models (GLMs) within a mega-
- analysis framework, with each sMRI measure (i.e., regional CT, SA or subcortical volume) as
- 312 the dependent variable and group (HC/CHR) or conversion status (CHR-PS+/CHR-PS-/HC) as

the independent variable. We included age,  $age^2$ , sex, and estimated total intracranial volume (ICV) as covariates in all models, and corrected for multiple comparisons (N=155) using the False Discovery Rate (FDR<sup>85</sup>) method. We considered *q*-values<0.05 statistically significant.

For all structural neuroimaging measures, we conducted pairwise comparisons and calculated Cohen's *d* effect sizes between two (CHR vs. HC) or three groups of interest (CHR-PS+ vs. HC/CHR-PS+ vs. CHR-PS-/CHR-PS- vs. HC). We also conducted analyses within a meta-analysis framework and fitted linear mixed models of sMRI data (not adjusted with neuroCombat), with scanner as a random effect. We investigated sMRI differences associated with the specific psychosis-risk syndromes (e.g., Attenuated Positive Symptom Syndrome; details in **Supplement**).

To evaluate the stability of group and conversion status differences, we performed analyses statistically controlling for psychotropic medication exposure at baseline. To assess effects of site, we conducted jackknife resampling analyses, i.e., iteratively removing one site's data and re-running respective analyses<sup>86,87</sup>. sMRI measures that failed to show a group or conversion status effect at q<0.05 in >10% of jackknife iterations (i.e., 4/31 sites) were considered "unstable".

To assess the meaningfulness of obtained effect sizes we used two analytic approaches: equivalence testing (to assess whether observed differences fell within the upper and lower bounds of a predefined smallest effect size of interest, providing support for the *absence* of a meaningful effect) and minimal-effects testing (to assess whether observed effects *were greater* than the same pre-defined effect size<sup>88</sup>). Upper/lower bounds (representing the positive/negative predefined smallest effect size of interest) were set to d = +/- 0.15 (further details and effect size rationale, see **Supplement**).

336

337 Group and conversion-related differences in sMRI age-associations

We used general additive models<sup>89,90</sup> to model group and conversion status differences 338 339 in the relationship between age and sMRI measures. General additive models extend GLMs by 340 allowing for a non-linear relationship between independent and dependent variables. Here, age 341 is modeled as a smooth function (continuous derivatives), which is akin to the "age-related" 342 slope in a GLM. Analyses were confined to sMRI measures that displayed statistically significant 343 effects of I) HC vs. CHR (N=56 measures) and II) CHR-PS+ vs. HC/CHR-PS+ vs. CHR-PS-344 /CHR-PS- vs. HC (N=4). We examined the effect of baseline age, group/conversion status, and the interaction between the two variables. Sex and estimated ICV were included as covariates. 345 Similar to prior work examining age effects during adolescent development<sup>91,92</sup>, we restricted 346 our sample's age range to 12-25 years (eTable 3). Details on post-hoc analyses for significant 347 348 interaction effects are provided in the Supplement.

349

350 Comparison of psychosis conversion-related effects to other ENIGMA findings

We computed Spearman's rank correlations to assess the extent to which the pattern of observed effect sizes (Cohen's *d's* for CHR-PS+ vs. HC and CHR-PS-) correlated with the pattern found in prior psychosis studies, specifically the ENIGMA Schizophrenia(SZ vs. HC<sup>69,70</sup>) and ENIGMA 22q11.2 Deletion Syndrome (22q11DS with psychosis vs. 22q11DS without psychosis<sup>72,73</sup>) Working Groups. As a control, we compared CHR-PS+/CHR-PS- vs. HC effect sizes to effect sizes published by the Major Depressive Disorder Working Group (MDD vs. HC<sup>93</sup>). Additional details of correlation analyses are reported in the **Supplement**.

### 358 3. RESULTS

359

### 360 Sample Characteristics

361 Site demographics are reported in Table 1. See eTables 4-6 for IQ and symptom
 362 comparisons. Few CHR participants reported typical (<1%) and/or atypical antipsychotic</li>
 363 (12.4%) medication use (eTable 7).

364

### 365 Widespread lower CT in CHR versus HC

Compared to HC, the CHR group had smaller global neuroimaging measures: estimated ICV (d=-0.13, CI=-0.2 to -0.06), mean CT (d=-0.18, CI=-0.25 to -0.11) and total SA (d=-0.15, CI=-0.22 to -0.08). Fifty-three additional regions exhibited a significant effect of group (q<0.05, **eTable 8**). The largest group effects were observed for widespread lower CT in CHR vs. HC (42/68 comparisons, d range=-0.09 to -0.17; **Figure 1A** for overview; **eTable 8** and **eFigure 1** for details). Few subcortical (3/16) and SA (8/68) group differences were observed (d range=-0.09 to -0.16). No group-by-sex interactions were detected (all q>0.05).

373 Group difference magnitudes remained similar when controlling for antipsychotic and 374 psychotropic medication use (**eTable 9**). 91% of group differences remained statistically 375 significant (q<0.05) in >90% of jackknife resampling iterations (eFigure 2), providing evidence 376 that site effects were not driving results. Equivalence testing revealed that effect sizes for group 377 differences were likely not meaningfully greater than our *a priori*-defined smallest effect size of 378 interest in 3/56 measures (**eFigure 1**, **eTable 10**).

Mega- and meta-analyses of neuroimaging data prior to neuroCombat harmonization provided similar results (Spearman's  $\rho$ >0.93; **eTable 11**). No sMRI measures were uniquely sensitive to psychosis-risk syndrome (see **Supplement** and **eTables 12-15** forresults).

### Thinner paracentral, fusiform, and superior temporal CT are associated with psychosis conversion

385 Forty-eight structural neuroimaging measures (N<sub>CT</sub>=37) exhibited a significant overall effect of psychosis conversion status (q < 0.05, Figure 1B; eFigure 3 and eTable 16). The three 386 387 groups differed from each other on four structural neuroimaging measures: in comparison to HC 388 and CHR-PS-, CHR-PS+ exhibited thinner cortex in bilateral paracentral, right superior 389 temporal, and left fusiform regions (Figure 1C, average d of four sMRI measures=-0.22). CHR-390 PS+ and CHR-PS- (vs. HC) exhibited thinner cortex in the left superior temporal and right 391 fusiform regions; similar trends were observed for CHR-PS+ vs. CHR-PS- differences (p<0.08; 392 Figure 1C). Results remained stable when length of follow-up period was included as a 393 covariate.

Using minimal-effects testing, we observed that effect sizes for bilateral paracentral (L 395 Z=-2.43, p=0.02; R Z=-1.86 p=0.06), right superior temporal (Z=-2.29, p=0.02) and left fusiform 396 (Z=-2.00, p=0.05) in CHR-PS+ vs. HC were all significantly *greater* than 0.15, at least at trend 397 level, underscoring the presence of notable group differences.

In the remaining follow-up comparisons, CHR-PS+ and CHR-PS- differed from HC at p<0.05, but there were no significant differences between CHR-PS+ and CHR-PS- (29/48 comparisons; **eTable 16**). We observed no conversion status-by-sex interactions (all q>0.05).

401 When we controlled for antipsychotic or psychotropic medication exposure, most overall 402 psychosis conversion effects remained statistically significant (eTable 17). sMRI measures that 403 differentiated the three groups showed an overall conversion effect at q < 0.05 in all jackknife 404 iterations, ruling out site effects as a potential confound (eFigure 2). No pairwise comparisons 405 for structural neuroimaging measures that showed an overall conversion effect at q < 0.05 were 406 statistically equivalent to our predefined smallest effect size of interest (eTable 18). There were 407 no statistically significant psychosis-risk syndrome-by-conversion status interactions (eTable 408 19).

### 410 CHR-PS+ fail to show expected age-associations with fusiform and paracentral CT

411 There were no significant group-by-age interactions in the 56 neuroimaging measures 412 that differed between CHR and HC (q>0.05, **eTable 20**). In contrast, 2/4 sMRI measures in 413 which all groups differed (HC vs. CHR-PS+ vs. CHR-PS-) displayed a statistically significant 414 conversion status-by-age interaction.

- In left fusiform, age-CT associations differed between CHR-PS+ vs. HC (F=9.8, p=4.9e-05, q=5.9e-04) and CHR-PS- vs. HC (F=8.7, p=1.5e-04, q=9.1e-04, Figure 2A, left). Between ages 12-16, HC showed a stronger negative association between age and CT, compared to CHR-PS+ and CHR-PS-, suggesting a reduced rate of CT change in CHR-PS+ and CHR-PS-.
- 419 Though the age-by-conversion status interaction was not statistically significant, a similar
- 420 pattern emerged for the right fusiform CT (Figure 2A, right).
- 421 Age-effects in the left paracentral CT differed between CHR-PS+ vs. HC (F=5.9, p=4.9e-422 03, q=0.02, Figure 2B, left). Between 12-15.8 years of age, HC showed a stronger negative 423 association between age and CT in comparison to CHR-PS+. Age-CT associations did not differ 424 between CHR-PS- vs. HC (F=0.2, p=0.69). This pattern of results was not observed for the right 425 paracentral CT (Figure 2B, right).

426 We found no significant age-by-conversion status interactions for the superior temporal 427 CT (Figure 2C); all three groups showed negative CT-age associations.

428

409

### 429 CT aberrations in CHR-PS+ resemble the pattern observed in SZ and 22q11DS with a 430 psychotic disorder diagnosis, but not MDD

431 Figure 3A provides a visual overview of CT alterations in CHR-PS+ relative to SZ and 432 individuals with 22q11DS and a psychotic disorder. The pattern of baseline CT alterations in 433 CHR-PS+ (CHR-PS+ vs. HC effect sizes) correlated significantly with that observed in SZ 434  $(\rho=0.35, \rho_{permute}=0.004, Figure 3B top)$  and individuals with 22q11DS and psychosis ( $\rho=0.43$ , 435 p<sub>permute</sub>=0.001, Figure 3B bottom). CT alterations in CHR did not correlate with those observed 436 in MDD (CHR-PS+ ρ=-0.03) and slopes for CHR-PS+/SZ and CHR-PS+/MDD correlations 437 significantly differed (Steiger's Z=2.06, p<sub>permute</sub>=0.008). No significant correlations were observed 438 for SA (SZ p=-0.03; 22g.11DS p=-0.06, eFigure 5). Subcortical volume alterations in CHR-PS+ 439 correlated with those observed in SZ ( $\rho$ =0.54,  $\rho$ =0.03) and a similar non-significant trend was 440 observed for 22q11DS and psychosis ( $\rho=0.46$ , p=0.07). Associations for CHR-PS- (vs. HC) 441 effect sizes were similar to those reported here (see Supplement).

442

#### 443 4. DISCUSSION

444

445 We conducted the largest multisite neuroimaging investigation to date in CHR 446 participants, examining baseline structural neuroimaging measures associated with later 447 transition to psychosis. We found widespread thinner cortex in CHR, consistent with previously-448 reported CT alterations in individuals with an established psychotic disorder. Compared to CHR-449 PS- and HC, at baseline, CHR-PS+ exhibited thinner cortex in bilateral paracentral, right 450 fusiform and left superior temporal regions, with effect sizes significantly greater than what we 451 considered to be meaningful a priori. Our results were robust to effects of medication exposure, 452 sex, site, and length of follow-up period. Findings from this international effort suggest that 453 conversion to psychosis amongst those at high risk is associated with thinner cortex at baseline.

454 We identified widespread regional thinner cortex in CHR compared to HC. Thinner cortex has been observed in SZ, as well as other psychiatric disorders<sup>69,79,93–95</sup>. Importantly, the 455 456 overall pattern of thinner cortex in CHR resembled that observed in SZ and individuals with 22q11DS and a psychotic disorder, but not in MDD. For CHR-PS+, correlations with SZ CT 457 alterations were significantly greater than the relationship observed with MDD CT alterations. 458 459 Taken together, our results suggest that the overall constellation of reported CT alterations 460 resembles the regional pattern of alterations observed in SZ and genetic disorders associated 461 with psychosis, and thus argues in favour of psychosis-specific thinner cortex in CHR

462 We also observed thinner cortex specific to psychosis conversion in paracentral, 463 superior temporal and fusiform CT; CHR-PS+ exhibit significantly lower CT than CHR-PS- and 464 HC in these regions. Lower baseline CT and/or volume in these regions has previously been reported in CHR-PS+<sup>96,97</sup> (data not used here). Furthermore, longitudinal CT decreases in these 465 regions have been associated with transition to psychosis in CHR<sup>17,98,99</sup>. The magnitude of 466 altered CT in CHR-PS+ in paracentral, superior temporal and fusiform regions was highly 467 consistent with findings in SZ<sup>70,100–102</sup> and lower fusiform and paracentral CT has been observed 468 in non-clinical voice hearers<sup>103</sup>. Thus, the observed pattern of CT alterations in CHR-PS+ is 469 470 consilient with morphometric disruptions across the wider psychosis spectrum.

471 Consistent with previous CHR studies examining baseline neuroimaging associations 472 with later conversion to psychosis<sup>96,104</sup>, we did not observe widespread subcortical volume or SA 473 alterations associated with later psychosis transition. Taken together, these results suggest that 474 CT reductions may be among the most widespread, robust, and specific morphometric changes 475 associated with psychosis risk and conversion, compared to SA or subcortical volume.

476 The neuroanatomic pattern of group differences and age-associated disruptions 477 observed in CHR may provide important insights into mechanisms underlying increased risk for psychosis. Pre-clinical models <sup>105,106</sup> and recent genome-wide association studies<sup>107</sup> suggest 478 479 that genetic variants associated with SZ are linked to the regulation of neural progenitor cells 480 during fetal development, while genetic markers associated with CT were associated with 481 regulatory processes in adulthood. Thus, CT alterations may be the end result of maladaptive 482 maturation-related mechanisms that occur during post-fetal development, including proliferation, synaptic pruning and/or myelination<sup>108–111</sup>. Thinner CT, particularly in early adolescence<sup>112,113</sup> 483 (Figure 2), could reflect abnormal synaptic plasticity or pruning, which have both been 484 implicated in *in vitro* SZ models<sup>114</sup>. Although excessive synaptic pruning is one plausible 485 486 explanation for thinner cortex associated with psychosis transition, recent evidence suggests

that intracortical myelination and/or expression of myelin-related genes may be mechanisms
 driving cortical thinning<sup>115,116</sup>. To better understand neurobiological mechanisms underlying
 psychosis transition in CHR, investigations of concomitant measures of cortical thickness,
 macroscale white matter tracts, and intracortical myelination are necessary.

491 Even if CT reductions in CHR were robust, effect sizes for between-group differences 492 were nevertheless small-to-moderate and accounted for ~1% of the variance in CHR-PS+ vs. 493 CHR-PS- comparisons. The subtle nature of these morphometric alterations underscores the 494 importance of adequate statistical power, achievable only through large-scale multi-site 495 collaborations. Consistent with recent work showing that SZ polygenic risk scores only improved differentiation of CHR-PS+ and HC (not CHR-PS+ from CHR-PS-)<sup>117</sup>, we anticipate that 496 baseline, univariate sMRI metrics will to have a similar impact on psychosis risk prediction 497 498 algorithms. Given the logistic and financial challenges that MRI brings, the use of MRI metrics in 499 isolation may not be feasible or useful for psychosis risk prediction. A viable solution may be to adopt sequential assessment frameworks, as recently implemented<sup>34</sup>. Alternatively, sMRI 500 501 alterations may be a better predictor of general psychopathology, and would be better suited for transdiagnostic risk prediction models<sup>118,119</sup>. 502

### 504 Limitations

505 One limitation common to multi-site studies is that data were collected from multiple 506 scanners, although leave-one-out analyses suggest that site effects were not prominent. 507 Secondly, this initial study focused on baseline cross-sectional data, and did not investigate 508 progressive sMRI changes (trajectories) associated with psychosis conversion, as identified in 509 prior work<sup>17,19,38,97–99,120–123</sup>. This is a future goal of the ENIGMA CHR Working Group, now that 510 feasibility of this collaboration has been established.

511

503

### 512 **Conclusions and Future Directions**

513 In the largest study of brain abnormalities in CHR to date, we found robust evidence for a 514 subtle, widespread pattern of CT alterations, consistent with observations in psychosis. The 515 specificity of these alterations to CT - as well as age-associated deviations in regions sensitive 516 to psychosis conversion - may point to abnormal development processes. These findings also 517 point to age ranges (i.e., early adolescence) when morphometric abnormalities in CHR might be 518 greatest.

519

### 520 Acknowledgements

521 BHE (Bjørn H. Ebdrup) is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-

- 522 Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has
- received lecture fees from Bristol-Myers Squibb, Otsuka Pharma Scandinavia AB, Eli
   Lilly Company, Boehringer Ingelheim Danmark A/S, and Lundbeck Pharma A/S. DH
- Lilly Company, Boehringer Ingelheim Danmark A/S, and Lundbeck Pharma A/S. DH (Dennis Hernaus) has received financial compensation as a consultant for P1vital
- 526 Produicts Ltd. F-RM (Francisco Reyes-Madrigal) has received compensation as a
- 527 speaker for Janssen (Johnson & Johnson). All reported activities were unrelated to the
- 528 work presented in this manuscript.
- 529

### 530 **References**

#### 531

- 5321.Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured533interview for prodromal syndromes and the scale of prodromal symptoms: predictive534validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703.
- 535 2. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring
  536 and care of young people at incipient risk of psychosis. *Schizophr Bull*. 1996;22(2):283537 303. doi:10.1093/schbul/22.2.283
- 538 3. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis. A step towards
  539 indicated prevention of schizophrenia. *Br J Psychiatry Suppl.* 1998;172(33):14-20.
- Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Arch Gen Psychiatry*. 2012;69(3):220-229. doi:10.1001/archgenpsychiatry.2011.1472
- 5435.Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for544psychosis. Schizophr Res. 2010;116(2-3):168-172. doi:10.1016/j.schres.2009.10.001
- Ruhrmann S, Schultze-Lutter F, Salokangas RKR, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. *Arch Gen Psychiatry*. 2010;67(3):241-251.
   doi:10.1001/archgenpsychiatry.2009.206
- 549 7. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of Psychosis in Youth at High
  550 Clinical Risk: A Multisite Longitudinal Study in North America. *Arch Gen Psychiatry*.
  551 2008;65(1):28. doi:10.1001/archgenpsychiatry.2007.3
- 5528.Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-553risk ("prodromal") group. Schizophr Res. 2003;60(1):21-32. doi:10.1016/s0920-5549964(02)00167-6
- 555 9. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The
  556 schizophrenia prodrome revisited: a neurodevelopmental perspective. *Schizophr Bull.*557 2003;29(4):633-651. doi:10.1093/oxfordjournals.schbul.a007036
- 558 10. Zhang T, Li H, Tang Y, et al. Validating the Predictive Accuracy of the NAPLS-2
  559 Psychosis Risk Calculator in a Clinical High-Risk Sample from the SHARP (Shanghai At Risk for Psychosis) Program. *Am J Psychiatry*. 2018;175(9):906-908.
  561 doi:10.1176/appi.ajp.2018.18010036
- Tor J, Dolz M, Sintes A, et al. Clinical high risk for psychosis in children and adolescents:
  a systematic review. *Eur Child Adolesc Psychiatry*. 2018;27(6):683-700.
  doi:10.1007/s00787-017-1046-3
- Hartmann JA, Yuen HP, McGorry PD, et al. Declining transition rates to psychotic
  disorder in "ultra-high risk" clients: Investigation of a dilution effect. *Schizophr Res.*2016;170(1):130-136. doi:10.1016/j.schres.2015.11.026
- Fusar-Poli P, Palombini E, Davies C, et al. Why transition risk to psychosis is not
  declining at the OASIS ultra high risk service: The hidden role of stable pretest risk
  enrichment. *Schizophr Res.* 2018;192:385-390. doi:10.1016/j.schres.2017.06.015
- 571 14. Bakker G, Caan MWA, Vingerhoets WAM, et al. Cortical Morphology Differences in
  572 Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison
  573 between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. *PLOS ONE*.
  574 2016;11(11):e0159928. doi:10.1371/journal.pone.0159928
- 575 15. Zikidi K, Gajwani R, Gross J, et al. Grey-matter abnormalities in clinical high-risk
  576 participants for psychosis. *Schizophr Res.* Published online November 15, 2019.
  577 doi:10.1016/j.schres.2019.08.034
- 578 16. Velakoulis D, Wood SJ, Wong MTH, et al. Hippocampal and Amygdala Volumes
  579 According to Psychosis Stage and Diagnosis: A Magnetic Resonance Imaging Study of
  580 Chronic Schizophrenia, First-Episode Psychosis, and Ultra–High-Risk Individuals. Arch

581 Gen Psychiatry. 2006;63(2):139. doi:10.1001/archpsyc.63.2.139 582 17. Sun D, Phillips L, Velakoulis D, et al. Progressive brain structural changes mapped as 583 psychosis develops in 'at risk' individuals. Schizophrenia Research. 2009;108(1-3):85-92. 584 doi:10.1016/j.schres.2008.11.026 Fornito A, Yung AR, Wood SJ, et al. Anatomic Abnormalities of the Anterior Cingulate 585 18. Cortex Before Psychosis Onset: An MRI Study of Ultra-High-Risk Individuals. Biological 586 587 Psychiatry. 2008;64(9):758-765. doi:10.1016/j.biopsych.2008.05.032 588 19. Takahashi T, Wood SJ, Yung AR, et al. Insular cortex gray matter changes in individuals 589 at ultra-high-risk of developing psychosis. Schizophrenia Research. 2009;111(1-3):94-102. doi:10.1016/j.schres.2009.03.024 590 591 Tomyshev AS, Lebedeva IS, Akhadov TA, Omelchenko MA, Rumyantsev AO, Kaleda 20. 592 VG. Alterations in white matter microstructure and cortical thickness in individuals at ultra-593 high risk of psychosis: A multimodal tractography and surface-based morphometry study. 594 Psychiatry Res Neuroimaging. 2019;289:26-36. doi:10.1016/j.pscychresns.2019.05.002 595 21. Kwak YB, Kim M, Cho KIK, Lee J, Lee TY, Kwon JS. Reduced cortical thickness in 596 subjects at clinical high risk for psychosis and clinical attributes. Aust NZJ Psychiatry. 597 2019;53(3):219-227. doi:10.1177/0004867418807299 598 22. Yassin W, Nakatani H, Zhu Y, et al. Machine-learning classification using neuroimaging 599 data in schizophrenia, autism, ultra-high risk and first-episode psychosis. Transl 600 Psychiatry. 2020;10(1):278. doi:10.1038/s41398-020-00965-5 601 23. Nakamura M, Takahashi T, Takayanagi Y, et al. Surface morphology of the orbitofrontal 602 cortex in individuals at risk of psychosis: a multicenter study. Eur Arch Psychiatry Clin 603 Neurosci. 2019;269(4):397-406. doi:10.1007/s00406-018-0890-6 604 24. Sasabayashi D, Takayanagi Y, Takahashi T, et al. Increased Occipital Gyrification and 605 Development of Psychotic Disorders in Individuals With an At-Risk Mental State: 606 A Multicenter Study. *Biol Psychiatry*. 2017;82(10):737-745. 607 doi:10.1016/j.biopsych.2017.05.018 608 25. Iwashiro N, Suga M, Takano Y, et al. Localized gray matter volume reductions in the pars 609 triangularis of the inferior frontal gyrus in individuals at clinical high-risk for psychosis and 610 first episode for schizophrenia. Schizophr Res. 2012;137(1-3):124-131. 611 doi:10.1016/j.schres.2012.02.024 612 26. Nakamura K, Takahashi T, Nemoto K, et al. Gray matter changes in subjects at high risk 613 for developing psychosis and first-episode schizophrenia: a voxel-based structural MRI 614 study. Front Psychiatry. 2013;4:16. doi:10.3389/fpsyt.2013.00016 Takayanagi Y, Kulason S, Sasabayashi D, et al. Reduced Thickness of the Anterior 615 27. 616 Cingulate Cortex in Individuals With an At-Risk Mental State Who Later Develop 617 Psychosis. Schizophr Bull. 2017;43(4):907-913. doi:10.1093/schbul/sbw167 618 28. Takahashi T, Tsugawa S, Nakajima S, et al. Thalamic and striato-pallidal volumes in 619 schizophrenia patients and individuals at risk for psychosis: A multi-atlas segmentation 620 study. Schizophr Res. Published online May 21, 2020. doi:10.1016/j.schres.2020.04.016 621 29. Buechler R, Wotruba D, Michels L, et al. Cortical Volume Differences in Subjects at Risk 622 for Psychosis are Driven by Surface Area. Schizophr Bull. Published online May 28, 623 2020. doi:10.1093/schbul/sbaa066 624 30. Chung Y, Allswede D, Addington J, et al. Cortical abnormalities in youth at clinical high-625 risk for psychosis: Findings from the NAPLS2 cohort. Neuroimage Clin. 2019;23:101862. 626 doi:10.1016/j.nicl.2019.101862 627 31. Chung Y, Addington J, Bearden CE, et al. Use of Machine Learning to Determine 628 Deviance in Neuroanatomical Maturity Associated With Future Psychosis in Youths at 629 Clinically High Risk. JAMA Psychiatry. 2018;75(9):960-968. 630 doi:10.1001/jamapsychiatry.2018.1543 631 Koutsouleris N, Meisenzahl EM, Davatzikos C, et al. Use of neuroanatomical pattern 32.

- 632 classification to identify subjects in at-risk mental states of psychosis and predict disease
  633 transition. Arch Gen Psychiatry. 2009;66(7):700-712.
  634 doi:10.1001/archgenpsychiatry.2009.62
- 635 33. Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, et al. Detecting the psychosis
  636 prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr
  637 Bull. 2015;41(2):471-482. doi:10.1093/schbul/sbu078
- Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S, et al. Prediction Models of Functional
  Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With RecentOnset Depression: A Multimodal, Multisite Machine Learning Analysis. JAMA Psychiatry.
  2018;75(11):1156-1172. doi:10.1001/jamapsychiatry.2018.2165
- Klauser P, Zhou J, Lim JKW, et al. Lack of Evidence for Regional Brain Volume or
  Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings
  From the Longitudinal Youth at Risk Study. *Schizophr Bull.* 2015;41(6):1285-1293.
  doi:10.1093/schbul/sbv012
- 36. Ziermans TB, Durston S, Sprong M, et al. No evidence for structural brain changes in
  young adolescents at ultra high risk for psychosis. *Schizophr Res.* 2009;112(1-3):1-6.
  doi:10.1016/j.schres.2009.04.013
- Takahashi T, Yücel M, Yung AR, et al. Adhesio interthalamica in individuals at high-risk
  for developing psychosis and patients with psychotic disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32(7):1708-1714.
  doi:10.1016/j.pnpbp.2008.07.007
- 653 38. Cannon TD, Chung Y, He G, et al. Progressive reduction in cortical thickness as
  654 psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated
  655 clinical risk. *Biol Psychiatry*. 2015;77(2):147-157. doi:10.1016/j.biopsych.2014.05.023
- Sakuma A, Obara Ć, Katsura M, et al. No regional gray matter volume reduction
  observed in young Japanese people at ultra-high risk for psychosis: A voxel-based
  morphometry study. Asian J Psychiatr. 2018;37:167-171. doi:10.1016/j.ajp.2018.09.009
- 40. Fusar-Poli P, Borgwardt S, Crescini A, et al. Neuroanatomy of vulnerability to psychosis:
  a voxel-based meta-analysis. *Neurosci Biobehav Rev.* 2011;35(5):1175-1185.
  doi:10.1016/j.neubiorev.2010.12.005
- Mechelli A, Riecher-Rössler A, Meisenzahl EM, et al. Neuroanatomical abnormalities that
  predate the onset of psychosis: a multicenter study. *Arch Gen Psychiatry*.
  2011;68(5):489-495. doi:10.1001/archgenpsychiatry.2011.42
- Farris MS, Devoe DJ, Addington J. Attrition rates in trials for adolescents and young
  adults at clinical high-risk for psychosis: A systematic review and meta-analysis. *Early Interv Psychiatry*. 2020;14(5):515-527. doi:10.1111/eip.12864
- 43. Schlosser DA, Jacobson S, Chen Q, et al. Recovery from an at-risk state: clinical and
  functional outcomes of putatively prodromal youth who do not develop psychosis. *Schizophr Bull.* 2012;38(6):1225-1233. doi:10.1093/schbul/sbr098
- 44. Rutigliano G, Valmaggia L, Landi P, et al. Persistence or recurrence of non-psychotic
  comorbid mental disorders associated with 6-year poor functional outcomes in patients at
  ultra high risk for psychosis. *J Affect Disord*. 2016;203:101-110.
  doi:10.1016/j.jad.2016.05.053
- 45. Simon AE, Borgwardt S, Riecher-Rössler A, Velthorst E, de Haan L, Fusar-Poli P. Moving
  beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical
  risk for psychosis. *Psychiatry Res.* 2013;209(3):266-272.
- 678 doi:10.1016/j.psychres.2013.03.004
- 679 46. Button KS, Ioannidis JPA, Mokrysz C, et al. Power failure: why small sample size
  680 undermines the reliability of neuroscience. *Nat Rev Neurosci.* 2013;14(5):365-376.
  681 doi:10.1038/nrn3475
- 682 47. Consideration of Sample Size in Neuroscience Studies. J Neurosci. 2020;40(21):4076-

683 4077. doi:10.1523/JNEUROSCI.0866-20.2020 684 48. Addington J, Cadenhead KS, Cornblatt BA, et al. North American Prodrome Longitudinal 685 Study (NAPLS 2): Overview and recruitment. Schizophrenia Research. 2012;142(1):77-82. doi:10.1016/j.schres.2012.09.012 686 Addington J. Liu L. Brummitt K. et al. North American Prodrome Longitudinal Study 687 49. (NAPLS 3): Methods and baseline description. Schizophrenia Research. Published online 688 689 April 18, 2020. doi:10.1016/j.schres.2020.04.010 690 50. Tognin S, van Hell HH, Merritt K, et al. Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating 691 692 Neuroimaging Findings From Research into Clinical Practice. Schizophr Bull. 693 2020;46(2):432-441. doi:10.1093/schbul/sbz067 694 51. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult 695 schizophrenia in the British 1946 birth cohort. Lancet. 1994;344(8934):1398-1402. 696 doi:10.1016/s0140-6736(94)90569-x 697 52. Lauronen E, Miettunen J, Veijola J, Karhu M, Jones PB, Isohanni M. Outcome and its 698 predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Eur Psychiatry. 699 2007;22(2):129-136. doi:10.1016/j.eurpsy.2006.07.001 700 53. Giedd JN, Blumenthal J, Jeffries NO, et al. Brain development during childhood and 701 adolescence: a longitudinal MRI study. Nature Neuroscience. 1999;2(10):861-863. 702 doi:10.1038/13158 703 54. Raznahan A, Shaw P, Lalonde F, et al. How Does Your Cortex Grow? Journal of 704 Neuroscience. 2011;31(19):7174-7177. 705 55. Sowell ER. Longitudinal Mapping of Cortical Thickness and Brain Growth in Normal 706 Children. Journal of Neuroscience. 2004;24(38):8223-8231. 707 56. Shaw P, Lerch J, Greenstein D, et al. Longitudinal mapping of cortical thickness and 708 clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. 709 Arch Gen Psychiatry. 2006;63(5):540-549. doi:10.1001/archpsyc.63.5.540 710 57. van Soelen ILC, Brouwer RM, van Baal GCM, et al. Genetic influences on thinning of the 711 cerebral cortex during development. Neuroimage. 2012;59(4):3871-3880. 712 doi:10.1016/j.neuroimage.2011.11.044 713 58. Vijavakumar N, Allen NB, Youssef G, et al. Brain development during adolescence: A 714 mixed-longitudinal investigation of cortical thickness, surface area, and volume. Hum 715 Brain Mapp. 2016;37(6):2027-2038. doi:10.1002/hbm.23154 716 Tamnes CK, Herting MM, Goddings A-L, et al. Development of the Cerebral Cortex 59. 717 across Adolescence: A Multisample Study of Inter-Related Longitudinal Changes in 718 Cortical Volume, Surface Area, and Thickness. J Neurosci. 2017;37(12):3402-3412. 719 doi:10.1523/JNEUROSCI.3302-16.2017 720 60. Mills KL, Goddings A-L, Herting MM, et al. Structural brain development between 721 childhood and adulthood: Convergence across four longitudinal samples. Neuroimage. 722 2016;141:273-281. 723 Mills KL, Goddings A-L, Clasen LS, Giedd JN, Blakemore S-J. The developmental 61. 724 mismatch in structural brain maturation during adolescence. Dev Neurosci. 2014;36(3-725 4):147-160. doi:10.1159/000362328 726 62. Mills KL, Tamnes CK. Methods and considerations for longitudinal structural brain 727 imaging analysis across development. Dev Cogn Neurosci. 2014;9:172-190. 728 doi:10.1016/j.dcn.2014.04.004 729 63. Mills KL, Lalonde F, Clasen LS, Giedd JN, Blakemore S-J. Developmental changes in the 730 structure of the social brain in late childhood and adolescence. Soc Cogn Affect Neurosci. 731 2014;9(1):123-131. doi:10.1093/scan/nss113 732 64. Bridgwater M, Bachman P, Tervo-Clemmens B, et al. Developmental influences on 733 symptom expression in antipsychotic-naïve first-episode psychosis. Psychol Med.

Published online October 6, 2020:1-12. doi:10.1017/S0033291720003463

734

735 65. Schimmelmann BG, Michel C, Martz-Irngartinger A, Linder C, Schultze-Lutter F. Age 736 matters in the prevalence and clinical significance of ultra-high-risk for psychosis 737 symptoms and criteria in the general population: Findings from the BEAR and BEARS-kid 738 studies. World Psychiatry, 2015;14(2);189–197. 66. Gerstenberg M, Theodoridou A, Traber-Walker N, et al. Adolescents and adults at clinical 739 740 high-risk for psychosis: age-related differences in attenuated positive symptoms 741 syndrome prevalence and entanglement with basic symptoms. Psychol Med. 2016;46(5):1069-1078. doi:10.1017/S0033291715002627 742 743 67. Schultze-Lutter F, Hubl D, Schimmelmann BG, Michel C. Age effect on prevalence of 744 ultra-high risk for psychosis symptoms: replication in a clinical sample of an early 745 detection of psychosis service. Eur Child Adolesc Psychiatry. 2017;26(11):1401-1405. 746 doi:10.1007/s00787-017-0994-y 747 Schultze-Lutter F, Schimmelmann BG, Flückiger R, Michel C. Effects of age and sex on 68. 748 clinical high-risk for psychosis in the community. World J Psychiatry. 2020;10(5):101-124. 749 doi:10.5498/wjp.v10.i5.101 750 van Erp TGM, Hibar DP, Rasmussen JM, et al. Subcortical brain volume abnormalities in 69. 751 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA 752 consortium. Molecular Psychiatry. 2016;21(4):547-553. doi:10.1038/mp.2015.63 753 70. van Erp TGM, Walton E, Hibar DP, et al. Cortical Brain Abnormalities in 4474 Individuals 754 With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biol Psychiatry. 2018;84(9):644-755 756 654. doi:10.1016/j.biopsych.2018.04.023 757 Okada N, Fukunaga M, Yamashita F, et al. Abnormal asymmetries in subcortical brain 71. 758 volume in schizophrenia. Mol Psychiatry. 2016;21(10):1460-1466. 759 doi:10.1038/mp.2015.209 760 72. Ching CRK, Gutman BA, Sun D, et al. Mapping Subcortical Brain Alterations in 22g11.2 761 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic 762 Neuropsychiatric Illness. AJP. Published online February 12, 2020:appi.ajp.2019.1. doi:10.1176/appi.ajp.2019.19060583 763 764 73. Sun D, Ching CRK, Lin A, et al. Large-scale mapping of cortical alterations in 22g11.2 765 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. 766 Mol Psychiatry. Published online June 13, 2018. doi:10.1038/s41380-018-0078-5 767 74. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-768 769 2194. doi:10.1001/jama.2013.281053 770 Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and 75. 771 surface reconstruction. Neuroimage. 1999;9(2):179–194. 772 Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and 76. a surface-based coordinate system. Neuroimage. 1999;9(2):195-207. 773 774 77. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic 775 resonance images. Proc Natl Acad Sci U S A. 2000;97(20):11050-11055. 776 doi:10.1073/pnas.200033797 777 78. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of 778 neuroanatomical structures in the human brain. Neuron. 2002;33(3):341-355. 779 Hibar DP, Westlye LT, Doan NT, et al. Cortical abnormalities in bipolar disorder: an MRI 79. 780 analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. Mol 781 Psychiatry. 2018;23(4):932-942. doi:10.1038/mp.2017.73 782 van Rooij D, Anagnostou E, Arango C, et al. Cortical and Subcortical Brain Morphometry 80. 783 Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals 784 Across the Lifespan: Results From the ENIGMA ASD Working Group. Am J Psychiatry.

785		2018;175(4):359-369. doi:10.1176/appi.ajp.2017.17010100
786	81.	Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in
787		participants with attention deficit hyperactivity disorder in children and adults: a cross-
788		sectional mega-analysis. Lancet Psychiatry. 2017;4(4):310–319.
789	82.	Boedhoe PSW, Schmaal L, Abe Y, et al. Cortical Abnormalities Associated With Pediatric
790		and Adult Obsessive-Compulsive Disorder: Findings From the ENIGMA Obsessive-
791		Compulsive Disorder Working Group. Am J Psychiatry. 2018;175(5):453-462.
792		doi:10.1176/appi.ajp.2017.17050485
793	83.	Radua J, Vieta E, Shinohara R, et al. Increased power by harmonizing structural MRI site
794		differences with the ComBat batch adjustment method in ENIGMA. <i>Neuroimage</i> .
795		2020;218:116956. doi:10.1016/j.neuroimage.2020.116956
796	84.	Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data
797	01.	using empirical Bayes methods. <i>Biostatistics</i> . 2007;8(1):118-127.
798		doi:10.1093/biostatistics/kxj037
799	85.	Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
800	00.	Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B
801		( <i>Methodological</i> ). 1995;57(1):289-300. doi:https://doi.org/10.1111/j.2517-
802		6161.1995.tb02031.x
803	86.	Efron B, Stein C. The Jackknife Estimate of Variance. Ann Statist. 1981;9(3):586-596.
804	00.	doi:10.1214/aos/1176345462
805	87.	Efron B. <i>The Jackknife, the Bootstrap, and Other Resampling Plans</i> . Society for Industrial
806	07.	and Applied Mathematics (SIAM, 3600 Market Street, Floor 6, Philadelphia, PA 19104);
807		1982.
808	88.	Lakens D. Equivalence Tests: A Practical Primer for t Tests, Correlations, and Meta-
809	00.	Analyses. Soc Psychol Personal Sci. 2017;8(4):355-362.
810		doi:10.1177/1948550617697177
811	89.	Hastie T, Tibshirani R. Generalized Additive Models. Statist Sci. 1986;1(3):297-310.
812	03.	doi:10.1214/ss/1177013604
813	90.	Hastie T, Tibshirani R. Generalized Additive Models. CRC Press; 1990.
814	90. 91.	Jalbrzikowski M, Larsen B, Hallquist MN, Foran W, Calabro F, Luna B. Development of
815	91.	White Matter Microstructure and Intrinsic Functional Connectivity Between the Amygdala
816		and Ventromedial Prefrontal Cortex: Associations With Anxiety and Depression. <i>Biol</i>
817		<i>Psychiatry</i> . 2017;82(7):511-521. doi:10.1016/j.biopsych.2017.01.008
818	92.	Marek S, Hwang K, Foran W, Hallquist MN, Luna B. The Contribution of Network
819	52.	Organization and Integration to the Development of Cognitive Control. <i>PLoS Biol.</i>
820		2015;13(12):e1002328. doi:10.1371/journal.pbio.1002328
821	93.	Schmaal L, Veltman DJ, van Erp TGM, et al. Subcortical brain alterations in major
822	95.	depressive disorder: findings from the ENIGMA Major Depressive Disorder working
823		group. Mol Psychiatry. 2016;21(6):806-812. doi:10.1038/mp.2015.69
823 824	04	
	94.	Rimol LM, Nesvåg R, Hagler DJ, et al. Cortical volume, surface area, and thickness in
825 826		schizophrenia and bipolar disorder. <i>Biol Psychiatry</i> . 2012;71(6):552-560.
820 827	05	doi:10.1016/j.biopsych.2011.11.026 Writing Committee for the Attention-Deficit/Hyperactivity Disorder, Autism Spectrum
	95.	
828		Disorder, Bipolar Disorder, et al. Virtual Histology of Cortical Thickness and Shared
829		Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> . Published online August 26, 2020. doi:10.1001/iamanayabiatry.2020.2604
830	00	2020. doi:10.1001/jamapsychiatry.2020.2694
831	96.	Del Re EC, Stone WS, Bouix S, et al. Baseline Cortical Thickness Reductions in Clinical
832		High Risk for Psychosis: Brain Regions Associated with Conversion to Psychosis Versus
833		Non-Conversion as Assessed at One-Year Follow-Up in the Shanghai-At-Risk-for-
834		Psychosis (SHARP) Study. <i>Schizophr Bull</i> . Published online September 14, 2020.
835		doi:10.1093/schbul/sbaa127

- 836 97. Borgwardt SJ, McGuire PK, Aston J, et al. Structural brain abnormalities in individuals
  837 with an at-risk mental state who later develop psychosis. *Br J Psychiatry Suppl.*838 2007;51:s69-75. doi:10.1192/bjp.191.51.s69
- 839 98. Pantelis C, Velakoulis D, Mcgorry PD, et al. Neuroanatomical abnormalities before and
  after onset of psychosis: a cross-sectional and longitudinal MRI comparison. *Lancet*.
  841 2003;361(9354):281–288.
- 842 99. Takahashi T, Wood SJ, Yung AR, et al. Progressive gray matter reduction of the superior
  843 temporal gyrus during transition to psychosis. *Arch Gen Psychiatry*. 2009;66(4):366-376.
  844 doi:10.1001/archgenpsychiatry.2009.12
- Lee CU, Shenton ME, Salisbury DF, et al. Fusiform gyrus volume reduction in firstepisode schizophrenia: a magnetic resonance imaging study. *Arch Gen Psychiatry*.
  2002;59(9):775-781. doi:10.1001/archpsyc.59.9.775
- Nonitsuka T, Shenton ME, Kasai K, et al. Fusiform gyrus volume reduction and facial
  recognition in chronic schizophrenia. *Arch Gen Psychiatry*. 2003;60(4):349-355.
  doi:10.1001/archpsyc.60.4.349
- Takahashi T, Suzuki M, Zhou S-Y, et al. Temporal lobe gray matter in schizophrenia
  spectrum: a volumetric MRI study of the fusiform gyrus, parahippocampal gyrus, and
  middle and inferior temporal gyri. *Schizophr Res.* 2006;87(1-3):116-126.
  doi:10.1016/j.schres.2006.04.023
- van Lutterveld R, van den Heuvel MP, Diederen KMJ, et al. Cortical thickness in individuals with non-clinical and clinical psychotic symptoms. *Brain*. 2014;137(Pt 10):2664-2669. doi:10.1093/brain/awu167
- 858 104. Sasabayashi D, Takayanagi Y, Takahashi T, et al. Subcortical Brain Volume
  859 Abnormalities in Individuals With an At-risk Mental State. *Schizophr Bull*. 2020;46(4):834860 845. doi:10.1093/schbul/sbaa011
- Pontious A, Kowalczyk T, Englund C, Hevner RF. Role of intermediate progenitor cells in cerebral cortex development. *Dev Neurosci*. 2008;30(1-3):24-32. doi:10.1159/000109848
- 106. Rakic P. Specification of cerebral cortical areas. *Science*. 1988;241(4862):170–176.
- 864107.Grasby KL, Jahanshad N, Painter JN, et al. The genetic architecture of the human865cerebral cortex. Science. 2020;367(6484). doi:10.1126/science.aay6690
- 866108.Huttenlocher PR. Synaptic density in human frontal cortex developmental changes and<br/>effects of aging. Brain Res. 1979;163(2):195-205. doi:10.1016/0006-8993(79)90349-4
- Rakic P, Bourgeois JP, Eckenhoff MF, Zecevic N, Goldman-Rakic PS. Concurrent
   overproduction of synapses in diverse regions of the primate cerebral cortex. *Science*.
   1986;232(4747):232-235. doi:10.1126/science.3952506
- Petanjek Z, Judas M, Kostović I, Uylings HBM. Lifespan alterations of basal dendritic
   trees of pyramidal neurons in the human prefrontal cortex: a layer-specific pattern. *Cereb Cortex.* 2008;18(4):915-929. doi:10.1093/cercor/bhm124
- Natu VS, Gomez J, Barnett M, et al. Apparent thinning of human visual cortex during
  childhood is associated with myelination. *Proc Natl Acad Sci U S A*. 2019;116(41):2075020759. doi:10.1073/pnas.1904931116
- Pantelis C, Yücel M, Wood SJ, et al. Structural brain imaging evidence for multiple
  pathological processes at different stages of brain development in schizophrenia. *Schizophr Bull.* 2005;31(3):672-696. doi:10.1093/schbul/sbi034
- Sun D, Stuart GW, Jenkinson M, et al. Brain surface contraction mapped in first-episode
  schizophrenia: a longitudinal magnetic resonance imaging study. *Mol Psychiatry*.
  2009;14(10):976-986. doi:10.1038/mp.2008.34
- Sellgren CM, Gracias J, Watmuff B, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. *Nat Neurosci.* 2019;22(3):374-385. doi:10.1038/s41593-018-0334-7
- 886 115. Whitaker KJ, Vértes PE, Romero-Garcia R, et al. Adolescence is associated with

887 888		genomically patterned consolidation of the hubs of the human brain connectome. <i>Proc Natl Acad Sci U S A</i> . 2016;113(32):9105-9110. doi:10.1073/pnas.1601745113
889	116.	Parker N, Patel Y, Jackowski AP, et al. Assessment of Neurobiological Mechanisms of
890		Cortical Thinning During Childhood and Adolescence and Their Implications for
891		Psychiatric Disorders. JAMA Psychiatry. Published online June 17, 2020.
892		doi:10.1001/jamapsychiatry.2020.1495
893	117.	
894		Psychosis Prediction in a Target Population of Persons at Clinical High Risk. Am J
895	440	<i>Psychiatry</i> . 2020;177(2):155-163. doi:10.1176/appi.ajp.2019.18060721
896	118.	Mei C, Nelson B, Hartmann J, Spooner R, McGorry PD. Chapter 4 - Transdiagnostic early
897 898		intervention, prevention, and prediction in psychiatry. In: Baune BT, ed. <i>Personalized</i>
899 899	119.	<i>Psychiatry</i> . Academic Press; 2020:27-37. doi:10.1016/B978-0-12-813176-3.00004-3 McGorry PD, Hartmann JA, Spooner R, Nelson B. Beyond the "at risk mental state"
900	119.	concept: transitioning to transdiagnostic psychiatry. World Psychiatry. 2018;17(2):133-
900 901		142. doi:10.1002/wps.20514
902	120.	Dazzan P, Soulsby B, Mechelli A, et al. Volumetric abnormalities predating the onset of
903	120.	schizophrenia and affective psychoses: an MRI study in subjects at ultrahigh risk of
904		psychosis. <i>Schizophr Bull</i> . 2012;38(5):1083-1091. doi:10.1093/schbul/sbr035
905	121.	
906		during development of psychosis. Schizophr Bull. 2012;38(3):519-530.
907		doi:10.1093/schbul/sbq113
908	122.	Walter A, Studerus E, Smieskova R, et al. Hippocampal volume in subjects at high risk of
909		psychosis: a longitudinal MRI study. Schizophr Res. 2012;142(1-3):217-222.
910		doi:10.1016/j.schres.2012.10.013
911	123.	
912		Predictive Utility of Support Vector Machine using Structural and Functional MRI Data.
913		Front Psychiatry. 2016;7:52. doi:10.3389/fpsyt.2016.00052
914		

### 915 **Table and Figure Legends**

916

Table 1. Demographic descriptives for every site in HC and CHR, and CHR-PS+ and CHR-PS-.
The Ns for CHR-PS+ and CHR-PS- do not always sum to the sample CHR N because most
sites lose individuals to follow-up (CHR-UNK).

920


921 Figure 1. Effect sizes for mega-analysis of group and conversion status. A. Overview of effect 922 sizes for HC vs. CHR. The top row reflects the results of the overall generalized linear model. A deeper purple color indicates a greater effect of group (HC vs. CHR) in this region. We 923 924 observed the greatest effects of group in cortical thickness measures. The second row indicates 925 the pairwise effect sizes for HC vs. CHR, in regions that were statistically significant (q < 0.05) in 926 the overall comparison (top row of A.). Regions that were not statistically significant in the 927 overall comparison are in gray. In comparison to HC, CHR exhibited lower cortical thickness 928 across the cortex. Red color indicates that HC has a larger value in comparison to CHR for this 929 region. B. Overview of effect sizes for HC vs. CHR-PS+ vs. CHR-PS-. The top row reflects the 930 results of the overall generalized linear model. A deeper purple color indicates a greater effect 931 of conversion status (HC vs. CHR-PS+ vs. CHR-PS-) in this region. The second and third rows 932 indicate the pairwise effect sizes for HC vs. CHR-PS+ and CHR-PS- vs. CHR-PS+, respectively. 933 Pairwise comparisons are presented in regions that were statistically significant (q<0.05) in the 934 overall comparison (top row of **B**.). Regions that were not statistically significant in the overall 935 comparison are in grav. Regions that CHR-PS+ had lower cortical thickness in comparison to 936 HC and CHR-PS-, CHR-PS+ are highlighted in yellow. C. Bar graphs for regions in which CHR-937 PS+ (pink) had lower CT in comparison to CHR-PS- (purple) and HC (green).


938

**Figure 2**. Age effects of regions that exhibited an effect of conversion status. HC are in green, CHR-PS+ are pink, and CHR-PS- are purple. Each graph has a line of best fit for the effect of age on the respective neuroimaging measures. Shading around the line indicates the standard error. The bars underneath the age plots reflect the derivative of the slope, i.e., the rate of change taking place at a particular age, scaled as a pseudo *t*-statistic, based on the posterior simulation. Age effects are plotted for A. fusiform cortical thickness, B. paracentral cortical thickness, and C. superior temporal cortical thickness.

946


Figure 3. Cortical thickness alterations in CHR-PS+, schizophrenia, and 22q.11DS A.
Magnitude of cortical thickness alterations for the three groups. Whole-brain cortical thickness
effect sizes were not reported for SZ and 22q.11DS in original publications; values shown are
the hemispheres with the smallest effect size. Colored bars represent standard error. B.
Spearman's rank correlations between cortical thickness alterations in CHR-PS+ and individuals
with schizophrenia (top) and 22q.11 DS with psychosis (bottom).






Lorem ipsum


### B Age vs. Paracentral Thickness



Age (years)

### C Age vs. Superior Temporal Thickness





А

	НС					CHR				CHR-PS+					CHR-PS-		Mean	
Site	N	% F	Mean Age (SD)	Age Range	N	% F	Mean Age (SD)	Age Range	N	% F	Mean Age (SD)	Age Range	N	% F	Mean Age (SD)	Age Range	Transition Rate	Follow-up Length (SD)
Amsterdam	23	57	23.4 (2.8)	19-32	16	62	23.6 (2.5)	20-30	0				16	62	23.6 (2.5)	20-30	   •	24 (0)
Barcelona-HSJD	44	41	15.6 (1.6)	13-18	55	58	15.2 (1.6)	11-18	7	43	15.7 (2.4)	12-18	35	66	15.2 (1.5)	11-18	16.7%	17.4 (4.8)
Bern	17	35	20.2 (6.1)	13-34	43	51	18.5 (5.1)	10-35	0		•	•	19	58	16.8 (3.8)	10-26	· •	15.8 (5.7)
Columbia1	9	22	24.4 (4.1)	20-33	17	53	22.9 (5)	15-31	3	67	19.4 (7.3)	15-28	14	50	23.6 (4.3)	16-31	17.6%	20.6 (10.3)
Columbia2	15	60	26.2 (2.2)	22-30	19	37	23.3 (3.6)	18-31	•	•	•	•	•	•	•	•	•	•
Columbia3	37	32	22.9 (3.6)	15-30	58	26	21 (4)	14-29	14	29	21.1 (4.8)	15-29	44	25	20.9 (3.8)	14-27	24.1%	24 (0)
Copenhagen	59	49	24.8 (3.3)	20-35	163	53	24.2 (4.2)	18-38	13	38	23.1 (3.4)	18-29	95	57	24.5 (4.6)	18-38	12%	11.8 (1.2)
CSU	59	42	21.5 (3.1)	15-30	52	46	19.5 (5)	13-35	21	57	19.4 (5.1)	13-35	31	39	19.5 (5)	13-30	40.4%	14.7 (7.6)
Glasgow	46	65	22.8 (3.6)	18-32	80	79	22.2 (4.8)	17-34	6	83	18.5 (1.9)	17-22	74	78	22.5 (4.8)	17-34	7.5%	20.2 (9.9)
Heidelberg	33	48	15.7 (0.9)	14-17	22	59	15.1 (1.1)	14-17	0	•	·	•	18	67	15.1 (1)	14-17	•	9.7 (3.3)
IDIBAPS	54	65	15.9 (1.6)	11-18	74	66	15.3 (1.7)	10-18	17	65	15.1 (1.4)	13-17	42	67	15.5 (1.9)	10-18	28.8%	14.3 (5.5)
ISMMS	12	42	27.9 (3.7)	23-35	25	52	23.4 (5.4)	17-35	1	0	26.3 (0)	26-26	12	58	23.6 (5.5)	17-35	7.7%	6 (0)
London	29	34	24.5 (4.7)	20-36	81	31	22.6 (4.4)	18-38	6	0	24 (4.4)	18-29	62	32	22.3 (4.6)	18-38	8.8%	18.8 (8.7)
Maastricht	38	32	25.6 (5.7)	18-39	48	29	20.2 (4.1)	12-29	6	33	20.5 (5.2)	15-26	25	32	18.6 (3.4)	12-27	19.4%	•
Melbourne	92	46	21.9 (3.6)	15-30	249	50	19.7 (3.4)	14-29	71	44	19.5 (3.5)	14-29	165	52	19.8 (3.4)	14-28	30.1%	71.4 (53.7)
Mexico City	38	26	20.9 (3.4)	15-28	33	21	19.5 (4.1)	13-31	7	29	20.4 (6)	15-31	26	19	19.3 (3.6)	13-27	21.2%	24 (0)
MHRC	51	0	22.2 (2.8)	16-27	38	0	20.1 (2.5)	16-28	3	0	19 (2.4)	16-21	35	0	20.2 (2.5)	17-28	7.9%	30.2 (6.6)
MPRC	20	40	17.8 (4.3)	12-24	31	52	17 (3.2)	12-22	3	33	16 (4.4)	13-21	10	50	15.8 (2.7)	12-20	23.1%	7.1 (1.1)
Newcastle	17	76	20.3 (1.9)	17-24	45	53	19.6 (2.2)	15-24	1	0	17.4 (0)	17-17	41	54	19.6 (2.2)	15-24	2.4%	21.5 (12)
Oslo Region	63	38	19.8 (3.6)	15-29	21	38	19.9 (3.6)	16-29	2	50	20 (5.4)	16-24	18	39	19.9 (3.7)	16-29	10%	12.5 (1.4)
Pitt	65	40	23 (5.9)	14-40	26	54	20.8 (5.3)	12-36	2	50	17.1 (0.8)	16-18	11	64	19.5 (6.4)	12-36	15.4%	13.1 (3.6)
RUMC	29	66	23.9 (3.2)	18-30	67	46	22.7 (3.9)	16-30	4	50	24.5 (2.9)	21-27	60	47	22.6 (3.9)	16-30	6.2%	8.3 (4.5)
Singapore	53	47	22 (4.2)	14-30	100	32	21.9 (3.6)	14-30	11	27	20.1 (3.1)	15-26	88	32	22.1 (3.6)	14-30	11.1%	18.9 (5.9)
SNUH	74	32	21.2 (2.5)	17-27	74	26	20.7 (3.8)	15-34	9	33	22 (5)	16-33	46	24	20.4 (3.7)	15-34	16.4%	30.9 (17.2)
Stavanger	33	48	17 (3.1)	13-27	37	59	16.6 (2.4)	13-25	5	80	16.2 (2.7)	13-19	31	58	16.7 (2.3)	14-25	13.9%	24 (0)
Toho	16	50	23.2 (2.9)	18-28	40	70	23.7 (6.9)	13-39	4	75	19 (4.4)	14-24	36	69	24.2 (7)	13-39	10%	12 (0)
Tokyo	25	48	22.1 (2.8)	16-25	39	46	20.9 (3.5)	14-29	3	0	22.7 (4.7)	19-28	25	60	20.5 (3.1)	14-27	10.7%	26.5 (12.1)
Toronto	39	41	25.5 (5.2)	18-38	27	44	20.8 (1.8)	18-27	0	•	•	•	4	50	19.7 (1.1)	18-21	•	24 (0)
Toyama	141	48	25.1 (4.2)	18-38	79	44	18.5 (4)	13-31	10	30	20.8 (5.7)	15-31	69	46	18.1 (3.7)	13-30	12.7%	37.4 (34.2)
UCSF	103	42	23.7 (7.5)	13-40	71	48	19.3 (4.4)	12-32	13	38	21.4 (4.4)	16-29	47	49	19 (4.1)	12-29	21.7%	21 (5.4)
Zurich	43	51	22.2 (5.6)	13-36	62	40	19.1 (4.9)	13-35	11	18	18.5 (3.4)	14-24	35	40	19.1 (5.3)	13-35	23.9%	

Table 1. Age and sex information for healthy controls (HC) and clinical high risk for psychosis (CHR) participants at each site

Follow-up times reported in months. "•" Indicates that data was not available, either because no CHR subjects transitioned to a psychotic disorder or follow-up data was not available. Site name abbreviations as follows: Amsterdam = Vrije Universiteit Amsterdam, The Netherlands; Barcelona-HSJD

= Hospital Sant Joan de Déu Barcelona, Barcelona, Spain; Bern = University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern. Switzerland: Columbia1 = New York State Psychiatric Institute. Columbia University. USA: Columbia2 = New York State Psychiatric Institute, Columbia University, USA; Columbia3 = New York State Psychiatric Institute, Columbia University, USA; Copenhagen = Mental Health Center Copenhagen and CINS, Mental Health Center Glostrup, University of Copenhagen, Denmark; CSU = Central South University, China; Glasgow = Institute of Neuroscience and Psychology, University of Glasgow, Scotland; Heidelberg = Heidelberg University Hospital, Germany; IDIBAPS = August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; ISMMS = Icahn School of Medicine at Mount Sinai, USA; London = Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK: Maastricht = Maastricht University, The Netherlands; Melbourne = University of Melbourne, Australia; Mexico City = Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico; MHRC = Mental Health Research Center Moscow, Russia; MPRC = Maryland Psychiatric Research Center, University of Maryland School of Medicine, USA; Newcastle = University of Newcastle, Australia; Oslo Region = NORMENT, University of Oslo and Oslo University Hospital, Norway; Pitt = University of Pittsburgh, USA; RUMC = Rush University Medical Center, Chicago, IL USA; Singapore = Institute of Mental Health, Singapore and National University of Singapore, Singapore; SNUH = Seoul National University, South Korea; Stavanger = Stavanger University Hospital, Norway; Toho = Department of Neuropsychiatry, Toho University School of Medicine, Japan; Tokyo = Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo; Toronto = Centre for Addiction and Mental Health, University of Toronto, Canada; Toyama = University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Japan; UCSF = University of California, San Francisco, USA; Zurich = Psychiatric Hospital, University of Zurich, Switzerland